California Public Employees Retirement System cut its stake in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 3.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 252,400 shares of the biopharmaceutical company’s stock after selling 7,900 shares during the period. California Public Employees Retirement System owned 0.69% of Tetraphase Pharmaceuticals worth $1,085,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Pacad Investment Ltd. raised its position in Tetraphase Pharmaceuticals by 144.5% in the first quarter. Pacad Investment Ltd. now owns 62,443 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 36,900 shares during the last quarter. Geode Capital Management LLC raised its position in Tetraphase Pharmaceuticals by 0.7% in the first quarter. Geode Capital Management LLC now owns 233,255 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,713 shares during the last quarter. Bellevue Group AG acquired a new position in Tetraphase Pharmaceuticals during the first quarter valued at approximately $102,000. Nisa Investment Advisors LLC raised its position in Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 41,900 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $257,000. 59.38% of the stock is owned by institutional investors and hedge funds.
Shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) traded up 1.18% on Monday, reaching $3.43. 111,973 shares of the company were exchanged. The stock’s market capitalization is $125.87 million. Tetraphase Pharmaceuticals Inc. has a 1-year low of $3.12 and a 1-year high of $12.45. The company has a 50-day moving average price of $3.77 and a 200 day moving average price of $4.25.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.01. Tetraphase Pharmaceuticals had a negative net margin of 821.25% and a negative return on equity of 35.43%. The firm earned $1.20 million during the quarter, compared to analyst estimates of $2.05 million. During the same period in the previous year, the firm posted ($0.72) EPS. The company’s revenue for the quarter was down 63.6% compared to the same quarter last year. On average, analysts forecast that Tetraphase Pharmaceuticals Inc. will post ($1.98) EPS for the current fiscal year.
TTPH has been the subject of several recent research reports. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Monday, June 20th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Wednesday, July 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $9.15.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH).
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.